CNBC: Inifiniti hopes new SUV can turn around fortunes in the U.S.

Infiniti is releasing a new midsize SUV, the QX65, in an effort to turn around sales in the U.S. market.

https://www.cnbc.com/2026/03/26/inifiniti-qx65-suv-nissan.html

CNBC: Is now the time to buy Nvidia? Cramer says ask these questions to arrive at an answer

The war in Iran has forced investors to act more like military strategists instead of stock-pickers, CNBC's Jim Cramer said Thursday.

https://www.cnbc.com/2026/03/26/cramer-when-to-buy-nvidia.html

CNBC: U.S. ambassador to EU: Stop fining Big Tech

Andrew Puzder sat down for an interview with CNBC's Ian King.

https://www.cnbc.com/2026/03/27/big-tech-eu-fines-ai-data-centers-us-ambassador-puzder.html

CNBC: ‘All bets are off’: European borrowing costs hit 15-year highs as investors brace for rate hikes

Bonds issued by various European countries continued to sell off on Friday, deepening a rout that has been mostly continuous since the U.S.-Iran war began.

https://www.cnbc.com/2026/03/27/european-bond-yields-inflation-rate-hikes.html

CNBC: Why one hedge fund veteran is urging investors to 'prepare for the worst'

DBi's Andrew Beer suggests the market's crystal ball is broken.

https://www.cnbc.com/2026/03/27/iran-to-economic-risks-markets-ability-to-forecast-world-in-question.html

CNBC: Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

https://www.cnbc.com/2026/03/27/novartis-nvs-stock-excellergy-buy-biotech-deal.html

CNBC: Senate advances DHS funding bill, tees up House vote to end shutdown as TSA lines stretch

Funding for the Department of Homeland Security lapsed in February, leading to chaos at aiports.

https://www.cnbc.com/2026/03/27/dhs-tsa-shutdown-congress.html

CNBC: AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

https://www.cnbc.com/2026/03/27/astrazeneca-stock-az-trial-lung-drug-shares-tozorakimab.html

CNBC: Markets now see the Fed's next move as a potential rate hike as inflation fears mount

Traders in the futures market shifted the probability of a rate increase by the end of 2026 to 52% on Friday morning.

https://www.cnbc.com/2026/03/27/markets-see-the-feds-next-move-as-a-potential-hike-as-oil-prices-inflation-fears-rise.html

CNBC: Elon Musk’s Grok ordered to stop creating AI nudes by Dutch court as legal pressure mounts

A Dutch court issued a $115,000 penalty for every day xAI fails to remove non-consensual AI-generated nude images created by its chatbot Grok.

https://www.cnbc.com/2026/03/27/grok-elon-musk-dutch-court-ban-ai-nudes.html

CNBC: Iran war wipes out $100 billion from luxury stocks

Dubai in the UAE has been the biggest driver of growth in recent years, and the Middle East tensions come at a critical time in the luxury industry.

https://www.cnbc.com/2026/03/27/iran-war-wipes-out-100-billion-from-luxury-stocks.html

CNBC: Rising oil prices could increase food costs—but hoarding groceries ‘makes a bad situation worse,’ economist says

Rising oil prices can take months to filter into grocery bills, and the impact is often smaller than consumers expect.

https://www.cnbc.com/2026/03/27/rising-oil-prices-lift-food-costs.html

CNBC: The key to this stock market is oil. Here's what investors need to consider

High oil prices create a difficult dynamic for companies, consumers, and investors.

https://www.cnbc.com/2026/03/27/the-key-to-this-stock-market-is-oil-what-investors-need-to-consider.html

CNBC: Gulf markets are splintering as the Iran war continues. Here's what to know

Investors are grappling with sharp divergence across the Gulf's markets, as the Iran conflict drives asset volatility in the region.

https://www.cnbc.com/2026/03/27/iran-war-oil-markets-middle-east-gulf-turmoil-strait-hormuz-investors.html

CNBC: Sony hikes PS5 prices by up to $150 citing 'pressures' in global economy

Sony, like other console makers, is contending with surging memory chip prices which have forced the company to raise prices.

https://www.cnbc.com/2026/03/27/sony-playstation-5-ps5-price-rise.html

CNBC: Every Cure’s drug repurposing strategy isn't what you think, and it could change rare disease treatment

When David Fajgenbaum and his colleagues launched the drug repurposing non-profit Every Cure, they chose a path that challenged the traditional research model.

https://www.cnbc.com/2026/03/27/every-cure-drug-repurposing-rare-disease-treatment.html

CNBC: Here are our top and bottom stocks over the past month. Not much green on the board

The stock market has spent the past month starved of good news.

https://www.cnbc.com/2026/03/27/here-are-our-top-and-bottom-stocks-over-the-past-month-not-much-green-on-the-board.html

CNBC: These Americans are quitting before AI can take their jobs—and starting their own businesses: 'I just wanted to be in control'

Americans are incorporating new businesses in record numbers, as AI sweeps across many U.S. workplaces. That's not a coincidence, some new entrepreneurs say.

https://www.cnbc.com/2026/03/27/how-ai-is-changing-american-entrepreneurship-small-business.html

CNBC: 1.4 million filers face tax refund delays amid IRS paper check phaseout

Many filers are facing tax refund delays amid the IRS push to phase out paper checks. Here's what to know if you receive a CP53E notice.

https://www.cnbc.com/2026/03/27/tax-refund-delays.html

CNBC: Cybersecurity stocks fall on report Anthropic is testing a powerful new model

The cybersecurity sector has slumped this year on fears that new AI will massively disrupt their business models.

https://www.cnbc.com/2026/03/27/anthropic-cybersecurity-stocks-ai-mythos.html

CNBC: Italy investigates Sephora and Benefit over skincare marketing to children

Italy's competition authority said the LVMH-owned cosmetic brands Sephora and Benefit used an "insidious marketing strategy" to appeal to tween consumers.

https://www.cnbc.com/2026/03/27/sephora-benefit-investigation-skincare-marketing-children-tween-italy.html